Zacks.com on MSN2h
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking ...
clinicaladvisor.com2h
Lumryz Approval Expanded to Include Pediatric Narcolepsy
Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown ...
Daily8h
Avadel's narcolepsy drug Lumryz gets USFDA approval for pediatric use
Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of ...
devdiscourse11h
Current Health News: Key Developments in Global Health Landscape
A summary of recent health news updates reveals declining Marburg cases in Rwanda, Texas suing a doctor over prescribing ...
Medscape21h
FDA OKs Once-Nightly Lumryz for Children with Narcolepsy
Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children ...